Monash IVF Group (MVF) H2 2025 earnings summary

Executive summary

• FY25 revenue grew 6.7% to $271.9m, with underlying EBITDA up 5.6% to $66.3m and underlying NPAT down 8.1% to $27.4m, in line with guidance despite challenging market conditions and industry activity declines.

• Reported NPAT was $25.7m, rebounding from a prior year loss of $5.9m impacted by a class action settlement.

• Market share declined by 70 basis points, primarily in Victoria and Queensland, as stimulated cycles fell 5% and new patient registrations dropped 7%.

• Succession planning ensured leadership stability; an independent review into clinic incidents was completed and recommendations are being implemented.

• No final FY25 dividend declared due to second-half earnings and cash flow considerations; intention to resume dividends in FY26 if NPAT guidance is met.

Financial highlights

• Revenue increased from $255m in FY24 to $271.9m in FY25, with domestic IVF contributing $6.5m and international business $2.1m.

• Underlying EBITDA margin was 24.4%, stable year-over-year.

• Operating cash flow conversion (excluding class action payments) was 86%, down from 103% last year, mainly due to timing of creditor payments.

• Net debt increased by $40.9m to $89.6m, mainly due to class action payments; net leverage ratio rose to 1.7x.

• CapEx was $14.5m (5.3% of revenue), focused on new facilities, lab upgrades, and IT.

Outlook and guidance

• FY26 underlying NPAT is expected between $20m and $23m, reflecting a 10% decline in new patient registrations, weak domestic IVF demand, and deferred price increases.

• Management anticipates mid-high single-digit growth resuming from FY27, with FY26 serving as a reset base.

• Operating cash conversion is expected to return to 90%-100% in FY26, and leverage ratio to remain flat at 1.7x.

• Board intends to resume dividends in FY26 if NPAT guidance is achieved.

• Industry growth in stimulated cycles projected at 2-3% p.a., with emerging drivers potentially adding 1-2% p.a.